Strengthening drug discovery support capabilities through the transfer of the mouse and antibody businesses within the Group
First written in FY2021. 3 of 6 entries say "Restated". Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1AdvancedAnnual report
「The Company had been preparing to integrate the management of the core companies 新薬リサーチセンター and 安評センター for the purpose of further streamlining business operations through the consolidation of management resources and strengthening competitiveness and sales capabilities. The companies merged as scheduled on 1 October 2024.」
The management integration of 安評センター, which handles mouse and nonclinical testing functions, and 新薬リサーチセンター was completed, moving the consolidation of the two companies’ management resources to the implementation stage and strengthening drug discovery support capabilities. - FY2024-Q3AdvancedAnnual report
「Through this management integration, the Company aims to maximize corporate value by integrating the two companies’ strong technologies and businesses to provide integrated end-to-end services.」
The Company indicated a policy of integrating, through the merger, the nonclinical pharmacology and clinical trial functions of 新薬リサーチセンター with the safety testing and genetically modified mouse functions of 安評センター. - FY2022-Q3RestatedAnnual report
「For the purpose of improving management efficiency and strengthening the functions of the drug discovery support business, on 1 April 2021 the Company transferred its genetically modified mouse business to its subsidiary 株式会社安評センター and its antibody business to its subsidiary 医化学創薬株式会社, respectively, and transitioned to a pure holding company structure.」
The Company reconfirmed the transfer of the mouse business to 安評センター and the antibody business to 医化学創薬, and the objective of improving management efficiency and strengthening the functions of the drug discovery support business. - FY2022-Q2RestatedAnnual report
「For the purpose of improving management efficiency and strengthening the functions of the drug discovery support business, on 1 April 2021 the Company transferred its genetically modified mouse business to its subsidiary 株式会社安評センター and its antibody business to its subsidiary 医化学創薬株式会社, respectively, and transitioned to a pure holding company structure.」
The Company reconfirmed that the genetically modified mouse business was transferred to 安評センター and the antibody business to 医化学創薬, and that the purpose was to improve management efficiency and strengthen the functions of the drug discovery support business. - FY2022-Q1RestatedAnnual report
「For the purpose of improving management efficiency and strengthening the functions of the drug discovery support business, on 1 April 2021 the Company transferred its genetically modified mouse business to its subsidiary 株式会社安評センター and its antibody business to its subsidiary 医化学創薬株式会社, respectively, and transitioned to a pure holding company structure.」
The Company reconfirmed that the genetically modified mouse business was transferred to 安評センター and the antibody business to 医化学創薬. It stated that the purpose of the business transfers was to improve management efficiency and strengthen the functions of the drug discovery support business. - FY2021First statedAnnual report
「The Company will transfer its mouse business to 安評センター, use 安評センター’s animal testing technology and accelerate the development of various humanized model mice currently under way. The Company will also transfer its antibody business to 医化学創薬. By incorporating the technology of the Company’s antibody business, 医化学創薬 aims to strengthen its development capabilities, reinforce its organizational structure by integrating human resources, and become a drug discovery venture with a strong technological foundation for drug discovery.」
The mouse business was transferred to 安評センター and the antibody business to 医化学創薬. Animal testing technology, antibody technology and human resources were consolidated within the respective companies with the aim of providing higher-value-added drug discovery support services and strengthening development capabilities.